Literature DB >> 29779777

Interleukin 23/interleukin 17 axis activated by Mycobacterium avium complex (MAC) is attenuated in patients with MAC-lung disease.

Chin-Chung Shu1, Jann-Yuan Wang1, Ming-Fang Wu2, Hsin-Chih Lai3, Bor-Luen Chiang4, Chong-Jen Yu5.   

Abstract

BACKGROUND: Mycobacterium avium complex (MAC)-lung disease (LD) is increasing in patients without human immunodeficiency virus infection. However, data on host vulnerability to MAC-related immune responses, and in particular the interleukin (IL)-23/IL-17 axis, are lacking.
METHODS: We enrolled 50 patients with MAC-LD, 25 age-matched patients with tuberculosis (TB) and 25 controls. We measured levels of plasma cytokines, and studied IL-12/IL-17 responses in macrophage and lymphocyte activation to MAC.
RESULTS: The plasma level of IL-17 in the MAC group was higher than in the TB and control groups. In in-vitro macrophage stimulation, the expression of IL-23 in macrophages was similar in the patients with MAC-LD and controls, although the expression of IL-12 p40 was lower in the patients with MAC-LD. In assays of lymphocyte activation, IL-17 was induced by MAC-primed macrophages, but its level was lower in the patients with MAC-LD and TB than in the controls. The expression of programmed death (PD)-1 receptor was higher in CD4+IL17A+ lymphocytes in the patients with MAC-LD, and the production of IL-17 was significantly increased by blockade of PD-1 and PD-ligand 1.
CONCLUSIONS: MAC induced a similar expression of IL-23 from macrophages in the patients with MAC-LD compared to the controls, but a lower expression of IL-17 from lymphocytes, which may be through an increased expression of PD-1. The macrophage response of IL-12 p40 was stronger than that of IL-12 p70, and higher in the controls during MAC disease, which may suggest another kind of MAC-related immune evasion.
Copyright © 2018. Published by Elsevier Ltd.

Entities:  

Keywords:  Interleukin 12; Interleukin 17; Interleukin 23; Lung disease; Mycobacterium avium complex

Mesh:

Substances:

Year:  2018        PMID: 29779777     DOI: 10.1016/j.tube.2018.03.001

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  6 in total

Review 1.  Non-tuberculous mycobacteria immunopathogenesis: Closer than they appear. a prime of innate immunity trade-off and NTM ways into virulence.

Authors:  Marisa Cruz-Aguilar; Antonia I Castillo-Rodal; René Arredondo-Hernández; Yolanda López-Vidal
Journal:  Scand J Immunol       Date:  2021-06-22       Impact factor: 3.889

2.  NLRP3 inflammasome is attenuated in patients with Mycobacterium avium complex lung disease and correlated with decreased interleukin-1β response and host susceptibility.

Authors:  Ming-Fang Wu; Chin-Chung Shu; Jann-Yuan Wang; Bo-Shiun Yan; Hsin-Chih Lai; Bor-Luen Chiang; Lawrence Shih-Hsin Wu; Chong-Jen Yu
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

Review 3.  RNA Sensing of Mycobacterium tuberculosis and Its Impact on TB Vaccination Strategies.

Authors:  Sanne Burkert; Ralf R Schumann
Journal:  Vaccines (Basel)       Date:  2020-02-04

4.  Immune defects in patients with pulmonary Mycobacterium abscessus disease without cystic fibrosis.

Authors:  Milou M F Schuurbiers; Mariolina Bruno; Sanne M H Zweijpfenning; Cecile Magis-Escurra; Martin Boeree; Mihai G Netea; Jakko van Ingen; Frank van de Veerdonk; Wouter Hoefsloot
Journal:  ERJ Open Res       Date:  2020-11-10

5.  Mycobacterium avium Modulates the Protective Immune Response in Canine Peripheral Blood Mononuclear Cells.

Authors:  Suji Kim; Hyun-Eui Park; Woo Bin Park; Seo Yihl Kim; Hong-Tae Park; Han Sang Yoo
Journal:  Front Cell Infect Microbiol       Date:  2021-01-14       Impact factor: 5.293

6.  Early IL-17A production helps establish Mycobacterium intracellulare infection in mice.

Authors:  Bock-Gie Jung; Buka Samten; Kristin Dean; Richard J Wallace; Barbara A Brown-Elliott; Torry Tucker; Steven Idell; Julie V Philley; Ramakrishna Vankayalapati
Journal:  PLoS Pathog       Date:  2022-04-01       Impact factor: 7.464

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.